Effectiveness of ecallantide (cas 460738-38-9) in treating angiotensin-converting enzyme inhibitor–induced angioedema in the emergency department
-
Add time:07/14/2019 Source:sciencedirect.com
BackgroundAngiotensin-converting enzyme inhibitor–induced angioedema (ACEI-AE) is mediated by bradykinin. There remains an unmet treatment need because these patients, when presenting to the emergency department (ED), do not respond to conventional therapies, such as antihistamines and corticosteroids.
We also recommend Trading Suppliers and Manufacturers of ecallantide (cas 460738-38-9). Pls Click Website Link as below: cas 460738-38-9 suppliers
Prev:ecallantide (cas 460738-38-9) for the Acute Treatment of Angiotensin-Converting Enzyme Inhibitor–Induced Angioedema: A Multicenter, Randomized, Controlled Trial
Next:Response time for ecallantide (cas 460738-38-9) treatment of acute hereditary angioedema attacks) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide (cas 460738-38-9), a novel kallikrein inhibitor07/18/2019
- ecallantide (cas 460738-38-9) (DX-88) for acute hereditary angioedema attacks: Integrated analysis of 2 double-blind, phase 3 studies07/17/2019
- Outcomes after ecallantide (cas 460738-38-9) treatment of laryngeal hereditary angioedema attacks07/16/2019
- Response time for ecallantide (cas 460738-38-9) treatment of acute hereditary angioedema attacks07/15/2019
- ecallantide (cas 460738-38-9) for the Acute Treatment of Angiotensin-Converting Enzyme Inhibitor–Induced Angioedema: A Multicenter, Randomized, Controlled Trial07/13/2019
- Analysis of hereditary angioedema attacks requiring a second dose of ecallantide (cas 460738-38-9)07/12/2019
- Characterization of Anaphylaxis After ecallantide (cas 460738-38-9) Treatment of Hereditary Angioedema Attacks07/11/2019
